Wildlife rangers search for Noosa crocodile after potential sighting
Rangers have been scouring the area from the air, land and water following the potential sighting by long-time angler James Graham.
He said he spotted the croc-shaped silhouette on his "fish finder" on the weekend, prompting a search of the Noosa River that continued last night.
A drone has been deployed and the search will continue today and into this evening.
Program coordinator Scott Booth said there had not been other public sightings since Mr Graham's report.
"We'd also expect to see a crocodile sitting out for long periods trying to soak up any sunshine on exposed banks near the edge of the water, and we just haven't seen that," Mr Booth said.
He said there was a chance the sighting involved a different animal.
"That's probably more indicative of potentially a dolphin or shark, or something like that moving across the bottom of the water," Mr Booth said.
Yesterday Mr Graham told the ABC he had spent time fishing off northern Queensland and had seen crocodiles on the fish-finder monitor before.
The habitat for Queensland crocodiles is thought to end at Gladstone's Boyne River, about 300km north of Noosa.
In recent months a crocodile was euthanased at Mary River and another was photographed at Inskip Point.
University of Queensland professor Craig Franklin said there were sometimes "stragglers" outside traditional crocodile habitats because a larger male has forced them out of their territory.
Professor Franklin said there were historical cases of crocodiles recorded as far south as the Brisbane and Logan rivers.
He said the reptiles generally made their way back north to warmer waters.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
2 hours ago
- ABC News
Fears Vitamin B6 levels in energy drinks like Red Bull and Monster could contribute to rise in B6 toxicity cases
Concerns are mounting over an ingredient in energy drinks that has been linked to a growing number of life-altering blood toxicity cases. Vitamin B6 is considered an essential vitamin and is widely available in a balanced diet, with a recommended daily intake of just 1.3mg — 1.7mg per day for adults. But debilitating health problems can occur when a manufactured form of B6 — also known as pyridoxine hydrochloride, pyridoxamine, or pyridoxal — is consumed in excess. A 250ml can of Red Bull contains 5 milligrams of Vitamin B6, a 500ml can of Mother 4.3 milligrams per serve and a 500ml can of BSC Energy 10mg. "There's no good reason why energy drinks need to have six times the recommended daily intake of B6 in them," George Institute food policy researcher, Associate Professor Alexandra Jones told 730. "And while it's unlikely that you would exceed the upper limit by drinking energy drinks alone, there is a subset of the population that are likely to be simultaneously consuming energy drinks and other supplements which could also contain high levels of B6," she said. B6 is added to thousands of vitamin supplements and fortified food products — from magnesium and zinc to breakfast cereals and protein bars. Blood test data obtained by 7.30 from Australian pathology labs Sullivan Nicolaides has revealed more than 2,700 'probable' cases of neuropathy or other health issues attributed to B6 blood toxicity have occurred since January this year. "Typical consumption patterns mean people are getting much higher doses, not just from the individual products but multiple products," Dr Terri-Lynne South, a dietitian and GP said. Dr South is one of several health practitioners advocating for tighter regulations — as more cases of B6 toxicity emerge. "For the energy drinks containing 10mg of B6 — if they were vitamin supplements — they'd have to show a warning on the label," Dr South told 7.30. "There's only one reason to have a supplement for B6 — and that's if there is proven deficiency or risk of deficiency." The Australian and New Zealand Food Standards agency (FSANZ) set the limit for B6 in energy drinks at 10mg per day, around the time Red Bull entered the Australian market. "Formulated caffeinated beverages must carry an advisory statement that no more than a 'one-day quantity' should be consumed if they contain certain substances, including vitamin B6," a spokesperson told 7.30. Last month the country's medicines regulator, the Therapeutic Goods Administration (TGA), made several recommendations It called for vitamin supplements with more than 50mg of B6 to be taken off shelves and moved behind pharmacy counters. A TGA delegate last month wrote that FSANZ should consider the "appropriateness of the 10 mg limit for vitamin B6 in formulated caffeinated beverages, considering the risks from the use of multiple products containing Vitamin B6." The same delegate also described the benefits of synthetic B6 as 'negligible', said labelling is 'inconsistent' and 'confusing' and called on the multi-billion-dollar complementary medicines sector to initiate education campaigns. A spokesperson for FSANZ said: "If evidence emerges that consumers are regularly exceeding safe intake levels, FSANZ would consider raising a proposal to review the current permissions." FSANZ did not answer questions regarding how it monitors such evidence. Ms Jones said the agency typically prioritises cases where the adverse effects are immediate, not cumulative. "They're very focused on the immediate health risks of a product, so whether it would make you sick overnight, for example," she said. Geoff Parker, the CEO of the Australian Beverages Council issued a statement on behalf of Australia's energy drinks companies. He didn't answer 7.30's questions and instead compared his sector's products against complementary medicines. "Laws regulating energy drinks in Australia are among the most stringent in the world," he told 7.30. "Some popular multivitamin supplements contain about 25 mg of B6 — at least five times the average B6 in energy drinks sold in Australia. "The ... upper level of safe intake [is] 50 mg a day for adults. The average level of B6 in energy drinks sold in Australia is approximately 2.1mg for a 250ml serve." The regulations however don't prevent unprecedented or unlikely cases. Matthew* began taking Berocca daily last August after a colleague recommended it for an afternoon energy boost. The 56-year-old has a prominent public profile and asked 7.30 not to use his real name. "I work in a high-pressure environment ... by mid-afternoon, the energy levels start to wane ... one of my colleagues was having a Berocca — he said 'it gives you a boost', so I tried it, and it turned into a habit." What started as a daily pick-me-up soon escalated — at times, he was having two Beroccas in one drink. Then came the symptoms. "I felt a tingle — some pins and needles — in my left hand, it moved up my arm, then to my right hand, then into my legs, there were terrible burning sensations." Concerned about stroke or heart problems, he underwent tests for blood cancer and multiple sclerosis. His doctor eventually suggested a neurologist. "I was poisoning myself while [I was] trying to work out how I've poisoned myself." Still, he continued taking Berocca but concedes he was likely taking too much of the product. After months of suffering came the call from his GP. "He said 'you have to stop taking vitamin supplements'… I said, 'what are you talking about? I've never taken vitamins' And he said 'it's Vitamin B6'." Tests revealed Matthew had nearly three times the toxic level of B6 in his bloodstream. He stopped taking Berocca immediately. And while his symptoms improved within weeks, some burning sensations remain. "I haven't had any peripheral neuropathy for a month," he said. The mental toll though has been severe. "I am so careful about the food that I put in my mouth, the restrictions I have on drinking, the fact I exercise religiously. "I've never had serious mental issues — I'm a glass-half-full person — I don't think I've got a propensity towards depression or anything like that. "But I certainly was depressed about this — this has rocked my world, mentally." There are no warnings on Berocca packaging. Instead, it claims to improve physical energy "when consumed daily for 28 days." Berocca's parent company, pharmaceutical giant Bayer, said it is "committed to consumer safety and regulatory compliance". "All our over-the-counter products ... comply fully with TGA labelling requirements, including ingredient disclosure, dosage, and safety warnings. We will continue to abide by TGA rules and requirements." In 2020 Monique's blood became toxic after consuming protein shakes and multivitamins, she never realised the combined B6 levels were extreme. "It took about a year to be diagnosed," the 35-year-old told 7.30. "The worst state that I was in was being bed-bound for about six months, once the vestibular migraine started and I lost my balance completely. Monique believes during her recovery her symptoms were exacerbated when unwittingly consuming small amounts of B6 in a fortified drink. "I was doing really well, I was exercising again, and carefully checking everything I was eating, but after nine months of improvement I became complacent — I didn't think to check the back of the label," she said. Monique could not provide evidence concluding the fortified drink was a causal factor. Dr South believes much of the marketing around B6 is misleading. "Most of these products, promoting B-vitamins, are marketed as 'energy-giving', and that comes from the understanding that a lot of these vitamins are co-factors of generating energy in cells," she told 7.30. "We're starting to see it in multivitamin minerals from the chemist, but we need better regulations in these higher food products, especially energy drinks. "This increases the impetus for regulators like Food Standards Australian New Zealand the Therapeutic Goods Administration to coordinate together, because it's about the cumulative risks of this amount of B6 being in our food supply. Watch 7.30, Mondays to Thursdays 7:30pm on ABC iview and ABC TV Do you know more about this story? Get in touch with 7.30 here.
The Australian
6 hours ago
- The Australian
Health Kick Podcast: Imagion Biosystems
Stockhead's health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim speaks with Imagion Biosystems (ASX:IBX) chairman Robert Proulx and company advisor Dr Leonardo Kayat Bittencourt. Did you know that X-ray technology was invented more than a century ago? You can thank German scientist Wilhelm Conrad Röntgen for that. Since then, diagnostic technology in the healthcare sector has made leaps and bounds, and one of the companies at the forefront is Imagion Biosystems. Tune in to hear how IBX is accelerating early detection of cancer, how their MagSense Technology works, and more. This podcast was developed in collaboration with Imagion Biosystems, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
News.com.au
8 hours ago
- News.com.au
Health Check: Cancer drug developers drive further positive Car-T results
Imugene and Chimeric have unveiled further promising results for their Car-T immune-oncology assets Rhythm Biosciences shares soar 18% on kit validation results While investors are picky, equity dollars continue to flow There's a long drive ahead, but Imugene (ASX:IMU) and Chimeric Therapeutics (ASX:CHM) are heading in the right direction with their Car-T therapies that trick up the body's T-cells to be better cancer fighters. Imugene shares this morning leaped 10%, after the company reported two additional 'partial responses' in its phase 1b trial. The study aims to combat relapsed diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer. Imugene's Car-T therapy, azer-cel, could result in the first 'off the shelf' Car-T treatment derived from donor cells (rather than the patient). The trial tally now stands at six 'complete responses' and five partial responses. A complete response is disappearance of signs of cancer – tentatively known as a cure. A partial response is a cancer reduction of at least 50%. In all, the trial has achieved an overall response rate of 79%. On July 14 Imugene said nine out of 12 patients had responded, prompting a circa $37 million capital raising. The first patients dosed (last year) remain cancer free at 15 months. They had not responded to several therapy attempts. The trial is underway at ten US sites and six local sites, including Sydney's Royal Prince Alfred Hospital. Cells are 'hard at work' Chimeric reports 'encouraging early results' after moving to a stronger dose in its phase I/II study. The trial tests the company's Car-T candidate CHM CDH17. Chimeric reports one patient with stable disease and "anti-tumour activity", with the lesion shrinking by 12%. The boffins define stable disease as no change in tumour size, or up to 30% shrinkage. One patient from the first dose cohort remains with stable disease eight months after dosing, with an 18% shrinkage. 'This is great progress,' says Chimeric CEO Dr Rebecca McQualter. 'We can see the cells are hard at work to more data'. The trial has enrolled patients with advanced colorectal cancer, gastric cancer and intestinal neuroendocrine tumours. CHM CDH17 targets CDH17, a cancer biomarker 'associated with poor prognosis and metastases in the most common gastrointestinal tumours'. Chimeric expects to enrol 15 patients in the phase I part of the study, with an expanded cohort for phase II. Rhythm's test validation is in the groove Rhythm Biosciences (ASX:RHY) shares today surged a sector-leading ing 18%, on further validation results of the company's Colostat bowel cancer assay. Having received its first kits from the manufacturer for final internal testing, the company tested them on new blood samples from patients with no bowel cancer at any of the stages (one to four). 'This study was critical as the initial intended use of Colostat is for symptomatic patients who could well have early and late-stage disease,' the company says. While Rhythm will complete further studies, the data on 300 patient samples shows that Colostat is equally effective at detecting bowel cancer across all stages. Rhythm will apply to the local National Association of Testing Authorities to have Colostat approved under the common-used laboratory-developed route. Lung imager breathes easier with deep-pocketed backer Friday's keen investor response to lung imager 4D Medical's 4D Medical's (ASX:4DX) funding arrangement with ProMedicus (ASX:PME) no doubt has to do with the mere 'vibe' of the latter taking an interest in the market minnow. In its first tie up with a listed peer, the $30 billion market cap Pro Medicus has extended a $10 million 'hybrid debt and equity loan' to 4D Medical. The duo don't compete with each other. 4D Medical will use the funds to develop its product pipeline and advance a US Food and Drug Administration (FDA) marketing application. This is for the company's ventilation perfusion product, for use in computed tomography. The loan attracts 12.5% interest and is repayable in cash and 'shares valued at the same amount as the cash repayment'. The deal is non-dilutive if the share price remains where is it, with 'upside alignment' for both parties if they perform strongly over the next two years. 4D also reported customer receipts of $1.61 million for the June quarter, up 19%, taking full-year receipts to $12 months to $5.38 million (up 87%). The company undertook 74,000 scans for the quarter, up 105% year on year. 4D had outflows of $9.47 million, down 16% compared with the March quarter. The company ended June with cash of $9.9 million, with a $6 million R&D tax refund due 'in coming weeks'. 4D Medical shares surged 30% on Friday and edged up a further 10% today. Spare us a dime? Other life companies are bringing in the dollars via traditional equity means. The developer of a non-radiation-based imaging for breast and other cancers, Imagion Biosystems (ASX:IBX) has raised $3.5 million in a two-tranche institutional placement. The price was 1.5 cents per share, a 10% discount. The funds will support Imagion's proposed phase II US trial for Her-2 breast cancers. Nyrada (ASX:NYR) has raised $8.25 million via a placement. The company is developing Xolatryp, which blocks a certain ion channel to protect key cells in vital organs when under stress. This could be after a blood clot or reperfusion (the sudden flow of blood returning to an organ or tissue). Nyrada is preparing for a phase IIa acute myocardial infarction trial and has nearly finished a phase I cardioprotection study. Kiwi diagnostics house Pacific Edge (ASX:PEB) has raised NZ$20.7 million in a placement and share purchase plan, having targeted NZ$20 million. US authorities recently cancelled reimbursement of the Pacific Edge's bladder cancer test Cxbladder, but the company is challenging the decision. Finally, foetal monitoring house HeraMED (ASX:HMD) has raised $1.98 million 1.2 cents a share, a 4.8% discount. Reporting latecomers: please wait to be seated Companies needed to lodge their quarterly reports within a month. But the ASX 'ushers' will still see them to their seats if they're not too late. The bourse on Friday suspended Syntara (ASX:SNT) for non-lodgment – but not for long. The myelofibrosis drug developer was allowed to resume trading, having lodged before the opening of Friday's trading. The quarterlies were due on Thursday. Syntara reported receipts of $78,000, cash outflow of $3.7 million and a $15 million cash balance. By the end of September, investors should expect final results from the company's phase II program that evaluated its drug candidate amsulostat, in 16 patients. An interim readout showed eight of 11 evaluable patients (73%) achieved a reduction of 50% or more in their myelofibrosis symptoms. Syntara awaits an FDA review of its application to start a follow-on phase II/III trial. Meanwhile, Syntara will seek shareholder approval to grant 4.769 million of incentive shares to CEO Gary Phillips, at nil consderation.
